Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Terameprocol - Erimos Pharmaceuticals

Drug Profile

Terameprocol - Erimos Pharmaceuticals

Alternative Names: CINelim; EM-1421; M4N; NSC 136955; Tetra-O-methyl nordihydroguaiaretic acid; Tetra-O-methyl-NDGA; Tetramethoxynordihydroguaiaretic acid; TMNDGA

Latest Information Update: 01 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer Erimos Pharmaceuticals
  • Class Antineoplastics; Lignans; Small molecules
  • Mechanism of Action Apoptosis stimulants; BIRC5 protein inhibitors; Cdc2 kinase inhibitors; Mitosis inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • No development reported Alzheimer's disease; Bacterial infections; Cervical intraepithelial neoplasia; Diabetes mellitus; Haematological malignancies; Head and neck cancer; Herpes simplex virus infections; HIV infections; Human papillomavirus infections; Influenza virus infections; Leukaemia; Obesity; Psoriasis; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 May 2018 Phase-I/II development for Glioblastoma is ongoing in USA
  • 03 May 2018 Erimos Pharmaceuticals initiates a phase I trial for Glioblastoma (Recurrent, Metastatic disease, Late stage disease, Second-line therapy or greater) in USA (PO) (NCT02575794)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top